Table 2.
Pt | Tissue | Brachyury | |
---|---|---|---|
% Positivity | Intensity | ||
6 | Breast primary tumor | 30 | + |
6 | Met+ lymph node (a) | 90 | + |
6 | Met+ lymph node (b) | 90 | + |
6 | Nonmet lymph node (c) | Neg | Neg |
9 | Breast primary tumor | Focal | + |
9 | Met+ lymph node (a) | 60 | ++ |
9 | Met+ lymph node (b) | 60 | ++ |
9 | Nonmet lymph node (c) | Neg | Neg |
31 | Pleura | 90 | + |
32 | Bone | 90 | ++ |
33 | Bone | 90 | + |
34 | Brain | 70 | ++ |
* Matched breast primary tumor and metastatic lymph nodes from two patients and metastatic lesions from additional patients were analyzed for brachyury expression by immunohistochemistry with a murine monoclonal anti-brachyury antibody (Abcam). Two lymph nodes positive for metastasis from each patient (a, b) and one lymph node negative for metastasis from the same patient (c) were assayed. Neg = negative; Met = metastatic; Pt = patient number.